Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 4.33% | 154.81 | 0.0% | $1863.66m | |
| NVAX | Novavax, Inc. | 4.39% | 231.23 | 92.9% | $1423.06m | |
| OCGN | Ocugen, Inc. | 36.88% | 10.95 | 0.0% | $1213.37m | |
| AMGN | Amgen, Inc. | -1.14% | 224.92 | 1.3% | $594.80m | |
| ILMN | Illumina, Inc. | -1.45% | 439.41 | 3.5% | $530.13m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.58% | 450.57 | 2.7% | $522.91m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.20% | 212.55 | 1.9% | $515.41m | |
| GILD | Gilead Sciences, Inc. | -2.21% | 61.40 | 1.0% | $485.52m | |
| BIIB | Biogen, Inc. | -1.58% | 272.88 | 1.7% | $380.18m | |
| BNGO | BioNano Genomics, Inc. | -2.89% | 9.73 | 0.0% | $374.38m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -0.59% | 152.75 | 2.0% | $371.25m | |
| CRSP | CRISPR Therapeutics AG | -1.25% | 125.69 | 0.6% | $292.02m | |
| EXAS | EXACT Sciences Corp. | 3.67% | 136.12 | 18.4% | $252.07m | |
| SGEN | Seagen Inc. | 0.68% | 151.11 | 5.8% | $212.33m | |
| VXRT | Vaxart, Inc. | -4.67% | 7.15 | 0.0% | $210.57m |
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.